Mesothelioma Blood Tests and Biomarkers - Revision history

MesotheliomaSupport: Fix structural reference errors: remove orphaned/duplicate refs (RON-2026-04-05-003)

2026-04-06T09:56:43Z

Fix structural reference errors: remove orphaned/duplicate refs (RON-2026-04-05-003)

← Older revision		Revision as of 09:56, 6 April 2026
Line 313:		Line 313:
	<ref name="asco_mpf">[https://ascopubs.org/doi/10.1200/PO.17.00282 Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma], JCO Precision Oncology</ref>		<ref name="asco_mpf">[https://ascopubs.org/doi/10.1200/PO.17.00282 Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma], JCO Precision Oncology</ref>
	<ref name="oup_mpf">[https://academic.oup.com/jalm/article/3/2/166/5603053 Elevated Serum MPF as a Predictor of Poor Survival in Mesothelioma and Primary Lung Cancer], Journal of Applied Laboratory Medicine</ref>		<ref name="oup_mpf">[https://academic.oup.com/jalm/article/3/2/166/5603053 Elevated Serum MPF as a Predictor of Poor Survival in Mesothelioma and Primary Lung Cancer], Journal of Applied Laboratory Medicine</ref>
	~~<ref name="pmc_new_biomarkers">[https://pmc.ncbi.nlm.nih.gov/articles/PMC4356891/ Discovery of New Biomarkers for Malignant Mesothelioma], PMC / National Library of Medicine</ref>~~
	<ref name="pmc_somamer">[https://pmc.ncbi.nlm.nih.gov/articles/PMC3463527/ Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals Using SOMAmer Technology], PMC / National Library of Medicine</ref>		<ref name="pmc_somamer">[https://pmc.ncbi.nlm.nih.gov/articles/PMC3463527/ Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals Using SOMAmer Technology], PMC / National Library of Medicine</ref>
	<ref name="pmc_hmgb1">[https://pmc.ncbi.nlm.nih.gov/articles/PMC4867109/ HMGB1 and Its Hyperacetylated Isoform Are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and Identify Mesothelioma Patients], PMC / National Library of Medicine</ref>		<ref name="pmc_hmgb1">[https://pmc.ncbi.nlm.nih.gov/articles/PMC4867109/ HMGB1 and Its Hyperacetylated Isoform Are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and Identify Mesothelioma Patients], PMC / National Library of Medicine</ref>
Line 333:		Line 332:
	<ref name="mesoatty_diagnosis">[https://mesotheliomaattorney.com/mesothelioma/diagnosis/ Mesothelioma Diagnosis Guide], MesotheliomaAttorney.com</ref>		<ref name="mesoatty_diagnosis">[https://mesotheliomaattorney.com/mesothelioma/diagnosis/ Mesothelioma Diagnosis Guide], MesotheliomaAttorney.com</ref>
	<ref name="mesoatty_bloodtests">[https://mesotheliomaattorney.com/mesothelioma/diagnosis/blood-tests/ Mesothelioma Blood Tests], MesotheliomaAttorney.com</ref>		<ref name="mesoatty_bloodtests">[https://mesotheliomaattorney.com/mesothelioma/diagnosis/blood-tests/ Mesothelioma Blood Tests], MesotheliomaAttorney.com</ref>
	~~<ref name="cancer_gov">[https://www.cancer.gov/types/mesothelioma Mesothelioma Treatment], National Cancer Institute</ref>~~
	</references>		</references>

MesotheliomaSupport: Add differentiated triple GEO format: At-a-Glance, Key Facts wikitable, FAQ, Quick Statistics, Get Help

2026-03-08T22:37:27Z

Add differentiated triple GEO format: At-a-Glance, Key Facts wikitable, FAQ, Quick Statistics, Get Help

Show changes

MesotheliomaSupport: Remove H1, convert exec summary to lead, add listicle

2026-02-24T06:41:12Z

Remove H1, convert exec summary to lead, add listicle

← Older revision		Revision as of 06:41, 24 February 2026
Line 8:		Line 8:
	{\| class="infobox" style="width:300px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:300px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
	\|-		\|-
	! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| [[Mesothelioma]] Biomarkers		! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Mesothelioma Biomarkers
	\|-		\|-
	\| colspan="2" style="padding:10px; text-align:center; font-style:italic; border-bottom:1px solid #dee2e6;" \| Blood-Based Diagnostic and Monitoring Tests		\| colspan="2" style="padding:10px; text-align:center; font-style:italic; border-bottom:1px solid #dee2e6;" \| Blood-Based Diagnostic and Monitoring Tests
Line 36:		Line 36:
	\|}		\|}

	= ~~Mesothelioma Blood Tests: 7 Biomarkers That Aid Early Detection~~ and ~~Monitoring~~ =		'''Blood-based biomarkers''' offer a minimally invasive approach to detecting, monitoring, and prognosticating '''malignant mesothelioma''' — an aggressive cancer with a median survival of approximately '''12 months''' from [[Mesothelioma_Diagnosis_and_Staging\|diagnosis]]. Fewer than '''5% of mesothelioma patients''' are diagnosed at stage I, making early detection through blood tests a critical area of research.<ref name="pmc_biomarkers_review" /><ref name="dandell_diagnosis" /> The '''MESOMARK assay''' — measuring '''soluble mesothelin-related peptides (SMRP)''' — is the only '''FDA-approved''' blood biomarker for mesothelioma, cleared in 2007 for monitoring treatment response in already-diagnosed patients. Meta-analyses of 28 studies report a pooled sensitivity of '''61%''' and specificity of '''87%'''. Emerging biomarkers including '''fibulin-3''', '''hyperacetylated HMGB1''', and the '''13-protein SOMAmer panel''' show higher accuracy in research settings, with the strongest evidence supporting multi-biomarker panels rather than any single marker.<ref name="pmc_circulating" /><ref name="bmjopen_smrp" /><ref name="pmc_somamer" /><ref name="mlc_diagnosis" />

	~~== Executive Summary ==~~		'''Mesothelioma blood tests and biomarkers at a glance:'''
			* '''MESOMARK: only FDA-approved test''' — cleared in 2007 for monitoring treatment response, with 61% pooled sensitivity and 87% specificity across 28 studies<ref name="bmjopen_smrp" />
	~~Blood~~-~~based biomarkers offer a minimally invasive approach to detecting,~~ monitoring, and ~~prognosticating malignant mesothelioma — an aggressive cancer with a median survival of approximately 12 months from [[Mesothelioma_Diagnosis_and_Staging\|diagnosis]]. Fewer than 5~~% ~~of mesothelioma patients are diagnosed at stage I, making early detection through blood tests a critical area of research.~~<ref name="~~pmc_biomarkers_review~~" /><ref name="~~dandell_diagnosis~~" />		* '''Soluble mesothelin 0.3 nM detection limit''' — SMRP levels correlate directly with tumor volume, enabling less invasive treatment monitoring than imaging<ref name="fda_mesomark" />
			* '''Fibulin-3 AUC of 0.94 in serum''' — outperforms SMRP (AUC 0.81) and osteopontin (AUC 0.83) in head-to-head comparisons<ref name="pmc_fibulin_meta" />
	~~The MESOMARK assay~~ — ~~measuring soluble mesothelin-related peptides~~ (~~SMRP~~) ~~— is the only FDA-approved blood biomarker for mesothelioma, cleared~~ in ~~2007 for monitoring treatment response in already~~-~~diagnosed patients. Meta~~-analyses of 28 studies report a pooled sensitivity of 61% and specificity of 87%. While useful for treatment monitoring, MESOMARK is not approved for primary diagnosis or population screening, and its sensitivity is insufficient to serve as a standalone diagnostic tool.<ref name="~~pmc_circulating~~" /><ref name="~~bmjopen_smrp~~" /><ref name="~~mlc_diagnosis~~" />		* '''Osteopontin 57% sensitivity''' — patients with serum levels above 350 ng/mL had median survival of only 5 months versus 15 months for low levels<ref name="pmc_osteopontin" />
			* '''HMGB1 100% sensitivity/specificity''' — hyperacetylated isoform discriminated all 22 mesothelioma patients from 20 asbestos-exposed controls in initial study<ref name="pmc_hmgb1" />
	~~Emerging biomarkers including fibulin-3, hyperacetylated HMGB1, and the~~ 13-protein ~~SOMAmer~~ panel ~~show higher accuracy in research settings~~. ~~The SOMAmer~~ classifier ~~achieved 92% overall accuracy with detection of~~ 88% of ~~early-~~stage disease. ~~The strongest evidence supports multi~~-~~biomarker panels rather than any single~~ marker~~, with a three-protein combination of~~ mesothelin, fibulin-3, and ~~HMGB1~~ achieving ~~an AUC~~ of 0.~~99 in one study~~.<ref name="~~pmc_somamer~~" /><ref name="~~pmc_hmgb1~~" /><ref name="~~mesonet_diagnosis~~" />		* '''SOMAmer 13-protein panel AUC 0.95''' — the most accurate multi-marker classifier, detecting 88% of stage I/II disease with 93.2% sensitivity<ref name="pmc_somamer" />
			* '''Three-marker combo AUC 0.99''' — mesothelin plus fibulin-3 plus HMGB1 achieved 96% sensitivity and 93% specificity in combination<ref name="mattioli_panel" />
			* '''MPF 50% reduction threshold''' — patients achieving this decrease during treatment had median overall survival of 22.3 versus 8.8 months<ref name="asco_mpf" />
			* '''miRNA 0% prediagnostic sensitivity''' — circulating microRNAs failed to detect mesothelioma in samples collected a median 8.9 months before clinical diagnosis<ref name="pmc_mirna_prediagnostic" />
			* '''Renal disease false positives''' — both mesothelin and MPF levels are elevated in decreased kidney function independent of malignancy, a major confounding factor<ref name="sciencedirect_renal" />

	== Key Facts ==		== Key Facts ==

MesotheliomaSupport: Internal linking: added 1 wiki links

2026-02-20T21:02:15Z

Internal linking: added 1 wiki links

← Older revision		Revision as of 21:02, 20 February 2026
Line 8:		Line 8:
	{\| class="infobox" style="width:300px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:300px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
	\|-		\|-
	! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Mesothelioma Biomarkers		! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| [[Mesothelioma]] Biomarkers
	\|-		\|-
	\| colspan="2" style="padding:10px; text-align:center; font-style:italic; border-bottom:1px solid #dee2e6;" \| Blood-Based Diagnostic and Monitoring Tests		\| colspan="2" style="padding:10px; text-align:center; font-style:italic; border-bottom:1px solid #dee2e6;" \| Blood-Based Diagnostic and Monitoring Tests

MesotheliomaSupport: Create comprehensive blood biomarkers page: MESOMARK, fibulin-3, osteopontin, MPF, SOMAmer, HMGB1, miRNA

2026-02-20T04:42:53Z

Create comprehensive blood biomarkers page: MESOMARK, fibulin-3, osteopontin, MPF, SOMAmer, HMGB1, miRNA

New page

{{#seo:
|title=Mesothelioma Blood Tests and Biomarkers: MESOMARK, Fibulin-3, HMGB1 & Emerging Diagnostics
|description=Comprehensive guide to blood-based biomarkers for mesothelioma including the FDA-approved MESOMARK assay, fibulin-3, osteopontin, HMGB1, SOMAmer panel, and microRNA signatures with sensitivity and specificity data.
|keywords=mesothelioma blood test, MESOMARK assay, SMRP mesothelioma, fibulin-3, osteopontin mesothelioma, HMGB1 asbestos, mesothelioma biomarkers, SOMAmer panel, mesothelioma early detection
|author=David Foster, Patient Advocate, Danziger & De Llano
|published_time=2026-02-19
}}
{| class="infobox" style="width:300px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
|-
! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" | Mesothelioma Biomarkers
|-
| colspan="2" style="padding:10px; text-align:center; font-style:italic; border-bottom:1px solid #dee2e6;" | Blood-Based Diagnostic and Monitoring Tests
|-
| style="padding:10px; font-weight:bold; width:40%; border-bottom:1px solid #dee2e6;" | Category
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Medical / Diagnostic
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA-Approved Test
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''MESOMARK (SMRP)'''
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | MESOMARK Sensitivity
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 61% (pooled)
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | MESOMARK Specificity
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 87% (pooled)
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Most Accurate Panel
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''SOMAmer 13-protein''' (AUC 0.95)
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Biomarkers Under Study
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 7+ markers
|-
| style="padding:10px; font-weight:bold;" | Key Limitation
| style="padding:10px;" | No single marker sufficient alone
|-
| colspan="2" style="background:#1a5276; padding:10px; text-align:center;" | [https://dandell.com/contact-us/ Free Case Review →]
|}

= Mesothelioma Blood Tests: 7 Biomarkers That Aid Early Detection and Monitoring =

== Executive Summary ==

Blood-based biomarkers offer a minimally invasive approach to detecting, monitoring, and prognosticating malignant mesothelioma — an aggressive cancer with a median survival of approximately 12 months from [[Mesothelioma_Diagnosis_and_Staging|diagnosis]]. Fewer than 5% of mesothelioma patients are diagnosed at stage I, making early detection through blood tests a critical area of research.<ref name="pmc_biomarkers_review" /><ref name="dandell_diagnosis" />

The MESOMARK assay — measuring soluble mesothelin-related peptides (SMRP) — is the only FDA-approved blood biomarker for mesothelioma, cleared in 2007 for monitoring treatment response in already-diagnosed patients. Meta-analyses of 28 studies report a pooled sensitivity of 61% and specificity of 87%. While useful for treatment monitoring, MESOMARK is not approved for primary diagnosis or population screening, and its sensitivity is insufficient to serve as a standalone diagnostic tool.<ref name="pmc_circulating" /><ref name="bmjopen_smrp" /><ref name="mlc_diagnosis" />

Emerging biomarkers including fibulin-3, hyperacetylated HMGB1, and the 13-protein SOMAmer panel show higher accuracy in research settings. The SOMAmer classifier achieved 92% overall accuracy with detection of 88% of early-stage disease. The strongest evidence supports multi-biomarker panels rather than any single marker, with a three-protein combination of mesothelin, fibulin-3, and HMGB1 achieving an AUC of 0.99 in one study.<ref name="pmc_somamer" /><ref name="pmc_hmgb1" /><ref name="mesonet_diagnosis" />

== Key Facts ==

{| class="wikitable" style="width:100%; margin:1em 0; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:12px; text-align:left;" | Key Facts: Mesothelioma Blood Tests and Biomarkers
|-
| style="padding:15px;" |
* '''Only FDA-approved test:''' MESOMARK assay (SMRP) — cleared in 2007 by Fujirebio Diagnostics
* '''MESOMARK sensitivity:''' 61% pooled across 28 studies; specificity 87%
* '''Best single marker:''' Fibulin-3 with AUC of 0.94 in serum-based studies
* '''Most accurate panel:''' SOMAmer 13-protein classifier — AUC 0.95, detecting 88% of stage I/II disease
* '''HMGB1 potential:''' Hyperacetylated HMGB1 showed 100% sensitivity and specificity in initial study (small sample, expression of concern published)
* '''Limitation:''' No single biomarker is sufficient for definitive mesothelioma diagnosis alone
* '''False positive causes:''' Renal disease, other cancers (pancreatic, ovarian), and inflammatory conditions can elevate biomarker levels
* '''MESOMARK purpose:''' Approved for monitoring — NOT for primary diagnosis or screening
* '''miRNA limitation:''' Fails to detect mesothelioma in prediagnostic samples (0% sensitivity at 98% specificity)
* '''Combination approach:''' Mesothelin + fibulin-3 + HMGB1 panel achieved AUC of 0.99 with 96% sensitivity
* '''MPF prognostic value:''' Patients with ≥50% MPF reduction during treatment had median OS of 22.3 vs. 8.8 months
* '''Tissue biopsy:''' Remains required for definitive diagnosis — [[Mesothelioma_Biopsy_Procedures|biopsy procedures]] confirm histologic subtype
|}

== What Is the MESOMARK Assay? ==

The MESOMARK assay is an enzyme-linked immunosorbent assay (ELISA) for the quantitative measurement of soluble mesothelin-related peptides (SMRP) in human serum. Mesothelin is a 71-kDa precursor protein that is cleaved into two products: the 31-kDa N-terminal megakaryocyte potentiating factor (MPF) and a 40-kDa C-terminal glycoprotein. After further processing, SMRP is released from the cell surface. SMRP levels correlate directly with tumor volume, permitting less invasive monitoring of treatment response than imaging alone.<ref name="wiki_mesomark" /><ref name="fda_mesomark" /><ref name="dandell_bloodtests" />

Developed by Fujirebio Diagnostics, Inc., MESOMARK received FDA clearance through a Humanitarian Device Exemption in January 2007. It remains the only FDA-approved serum biomarker test for mesothelioma and is available through reference laboratories such as ARUP Laboratories. The assay has an analytical sensitivity of 0.3 nM with a dynamic range extending to approximately 26.69 nM.<ref name="fujirebio" /><ref name="arup_mesomark" /><ref name="mlc_bloodtests" />

=== Sensitivity and Specificity ===

Meta-analytic evidence provides the most robust performance estimates for MESOMARK:<ref name="bmjopen_smrp" /><ref name="pmc_biomarkers_review" />

{| class="wikitable" style="width:100%; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Study
! style="background:#1a5276; color:white; padding:10px;" | Sensitivity
! style="background:#1a5276; color:white; padding:10px;" | Specificity
! style="background:#1a5276; color:white; padding:10px;" | AUC
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Meta-analysis of 28 serum studies
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 61%
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 87%
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 0.806
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 12-study meta-analysis (717 MM, 2,851 controls)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 64%
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 89%
| style="padding:10px; border-bottom:1px solid #dee2e6;" | —
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Hollevoet individual patient data (16 studies)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 32% (at 95% specificity)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 95%
| style="padding:10px; border-bottom:1px solid #dee2e6;" | —
|-
| style="padding:10px;" | Pleural fluid SMRP (pooled)
| style="padding:10px;" | 79%
| style="padding:10px;" | —
| style="padding:10px;" | —
|}

SMRP performs best for the epithelioid histological subtype and may remain at normal levels even in patients with sarcomatoid mesothelioma. Pleural fluid SMRP has higher sensitivity (79%) compared to serum (61%), but obtaining pleural fluid requires thoracentesis rather than a simple blood draw.<ref name="bmjopen_smrp" /><ref name="mesonet_bloodtests" />

{| style="width:95%; margin:1em auto; border:1px solid #dee2e6; border-left:4px solid #1a5276; border-radius:4px;"
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "MESOMARK is a valuable tool for tracking treatment response in patients already diagnosed with mesothelioma, but patients and families should understand it is not designed as a screening test for undiagnosed individuals — even those with known asbestos exposure history."
|-
| style="padding:5px 25px 20px; text-align:right;" | '''— David Foster,''' Patient Advocate, Danziger & De Llano
|}

== What Is Fibulin-3 and How Does It Compare to MESOMARK? ==

Fibulin-3 is a secreted glycoprotein encoded by the EFEMP-1 gene, involved in regulating mesothelioma cell proliferation and migration. First proposed as a mesothelioma biomarker by Pass et al. in a landmark 2012 ''New England Journal of Medicine'' study, the initial report was extraordinary: 96.7% sensitivity and 95.5% specificity for distinguishing mesothelioma from controls. However, subsequent validation studies produced highly variable results.<ref name="nejm_fibulin" /><ref name="pmc_biomarkers_review" /><ref name="dandell_diagnosis" />

Meta-analyses have tempered the initial enthusiasm while confirming fibulin-3's potential superiority over SMRP. A meta-analysis of 7 studies (468 MM cases) found pooled sensitivity of 62% and specificity of 82% (AUC 0.81). However, serum-based assays showed notably better performance than plasma-based assays — sensitivity of 77% versus 54%, specificity of 85% versus 77%, and AUC of 0.92 versus 0.69 — suggesting sample type significantly affects diagnostic accuracy.<ref name="pmc_fibulin_meta" /><ref name="oncotarget_fibulin" /><ref name="mlc_bloodtests" />

In head-to-head comparisons, the AUC for blood fibulin-3 (0.94) exceeded that of both SMRP (0.81) and osteopontin (0.83). The DIAPHRAGM prospective multicenter study was designed to definitively validate these findings. A key limitation remains the variability between studies, with some reporting sensitivity as low as 12.7–59%.<ref name="bmjopen_diaphragm" /><ref name="mesoatty_diagnosis" />

== What Role Does Osteopontin Play in Mesothelioma Diagnosis? ==

Osteopontin (OPN) is a secreted glycoprotein involved in cell-matrix interaction and tumor migration. Pass et al. (2005) first linked elevated serum OPN to mesothelioma, reporting 77.6% sensitivity and 85.5% specificity. A subsequent meta-analysis of seven publications with ten studies established pooled sensitivity of 57%, specificity of 81%, and AUC of 0.85.<ref name="pmc_osteopontin" /><ref name="pmc_biomarkers_review" />

Osteopontin also carries prognostic significance: patients with high serum levels (>350 ng/mL) had median survival of only 5 months compared to 15 months for patients with low levels. However, OPN is elevated in multiple other cancers — including colon, lung, breast, and prostate cancer — limiting its specificity for mesothelioma. Plasma OPN outperforms serum OPN for diagnostic purposes because thrombin-related protein degradation during serum processing reduces accuracy.<ref name="pmc_osteopontin" /><ref name="dandell_treatment" /><ref name="mesonet_diagnosis" />

== What Is Megakaryocyte Potentiating Factor? ==

Megakaryocyte potentiating factor (MPF) is a 31-kDa secreted cytokine produced from the same MSLN gene precursor protein as mesothelin/SMRP. When the 71-kDa mesothelin precursor is cleaved by furin, it yields the N-terminal MPF and the C-terminal membrane-bound mesothelin. A prospective multicenter study of 507 participants found that both SMRP and MPF differentiated mesothelioma patients from controls (P<0.001), with no significant difference between the two markers (AUC: SMRP 0.871, MPF 0.849).<ref name="hindawi_mpf" /><ref name="pmc_systematic" /><ref name="mlc_treatment" />

MPF shows particular promise as a prognostic biomarker and potential companion diagnostic for mesothelin-targeted immunotherapies. Elevated serum MPF predicts poor survival (HR 2.46, P=0.003), and in refractory mesothelioma, elevated MPF was an even stronger predictor (HR 6.12, P=0.0007). Patients receiving mesothelin-targeted therapy who achieved a ≥50% reduction in MPF had dramatically improved progression-free survival (median 11.3 vs. 1.9 months) and overall survival (22.3 vs. 8.8 months, P=0.004).<ref name="asco_mpf" /><ref name="oup_mpf" /><ref name="dandell_bloodtests" />

== What Is the SOMAmer 13-Protein Classifier? ==

The SOMAmer (Slow Off-rate Modified Aptamer) proteomic panel represents the most promising multi-biomarker approach for mesothelioma detection. Developed by SomaLogic using the SOMAscan platform — which simultaneously measures over 1,000 proteins in unfractionated biological samples — researchers discovered 64 candidate biomarkers and derived a 13-marker random forest classifier from multicenter studies of 117 MM patients and 142 asbestos-exposed controls.<ref name="pmc_somamer" /><ref name="dandell_diagnosis" />

{| class="wikitable" style="width:100%; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Validation Phase
! style="background:#1a5276; color:white; padding:10px;" | AUC
! style="background:#1a5276; color:white; padding:10px;" | Key Finding
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Training set
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 0.99 ± 0.01
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Near-perfect discrimination
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Blinded verification
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 0.98 ± 0.04
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Maintained in independent set
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Blinded validation
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 0.95 ± 0.04
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Confirmed in real-world conditions
|-
| style="padding:10px;" | Combined (sensitivity/specificity)
| style="padding:10px;" | —
| style="padding:10px;" | 93.2% sensitivity, 90.8% specificity
|}

The 13 classifier proteins — 9 upregulated and 4 downregulated — had not previously been associated with mesothelioma. Their functions fall into two groups: regulation of proliferation and inflammation. This multiplex approach far outperformed single-marker mesothelin testing (AUC 0.82, sensitivity 66%, specificity 88%) in the same populations. The DIAPHRAGM prospective multicenter study was designed to validate the SOMAmer panel in a clinically relevant setting.<ref name="bmjopen_diaphragm" /><ref name="pmc_somamer" /><ref name="mesonet_treatment" />

== What Is Hyperacetylated HMGB1? ==

High-Mobility Group Box 1 (HMGB1) is a damage-associated molecular pattern protein that plays a central role in asbestos carcinogenesis. When asbestos fibers lodge in the pleura, mesothelial cells undergo programmed necrosis and release non-acetylated HMGB1, triggering chronic inflammation. Mesothelioma cells become dependent on HMGB1, actively secreting the hyperacetylated isoform to sustain their own growth.<ref name="pmc_hmgb1" /><ref name="mlc_diagnosis" />

In a 2016 study published in ''Clinical Cancer Research'', Napolitano, Carbone, and Pass measured HMGB1 isoforms in MM patients (n=22), asbestos-exposed individuals (n=20), and healthy controls (n=20). At a cutoff of 2.00 ng/mL, hyperacetylated HMGB1 discriminated MM patients from asbestos-exposed individuals with 100% sensitivity and 100% specificity (AUC 1.000). Total HMGB1 distinguished asbestos-exposed individuals from healthy controls with AUC of 0.964, and levels did not vary with tumor stage — suggesting potential for early detection.<ref name="pmc_hmgb1" /><ref name="dandell_bloodtests" />

=== Important Caveats ===

An expression of concern was published in 2020 regarding the integrity of mass spectrometry data contributed by one co-author. The small sample size (22 MM patients) raises the risk of data overfitting, and independent large-scale validation has not yet been completed. Potential confounders include alcoholic liver disease, which can elevate hyperacetylated HMGB1, though distinguishable by phosphorylation patterns. NCI-EDRN-funded validation studies were planned.<ref name="aacr_hmgb1_concern" /><ref name="mesoatty_bloodtests" />

== Can MicroRNAs Detect Mesothelioma Early? ==

MicroRNAs (miRNAs) are small non-coding RNAs (18–22 nucleotides) that are stable in blood and have been investigated as potential mesothelioma biomarkers. Several individual miRNAs show promise: miR-103a-3p achieved 83% sensitivity and 71% specificity for MPM versus asbestos-exposed controls, and when combined with mesothelin, sensitivity reached 95% with 81% specificity. A 6-miRNA prognostic signature predicted long survival after surgery with 92.3% accuracy.<ref name="exploration_mirna" /><ref name="pmc_biomarkers_review" /><ref name="mesonet_bloodtests" />

However, miRNAs have a critical limitation for early detection. A nested case-control study using prediagnostic plasma samples (collected median 8.9 months before clinical diagnosis) found that miR-132-3p, miR-126-3p, and miR-103a-3p showed 0% sensitivity at 98% specificity for detecting mesothelioma prior to clinical diagnosis. By contrast, protein biomarkers such as mesothelin and calretinin detected the tumor in prediagnostic samples up to 15 months before clinical diagnosis with 46% sensitivity. This suggests miRNAs may be useful for prognosis in patients with established disease but fail at truly early detection.<ref name="pmc_mirna_prediagnostic" /><ref name="dandell_diagnosis" />

== What Are the Limitations of Blood-Based Biomarkers? ==

No single biomarker has achieved sufficient sensitivity and specificity to serve as a standalone diagnostic tool for mesothelioma. A systematic review concluded that no serum or pleural fluid biomarker could be recommended for routine clinical practice at this time, though falling SMRP may correlate with treatment response.<ref name="pmc_systematic" /><ref name="pmc_calretinin" /><ref name="mlc_treatment" />

=== False Positive Causes ===

Several conditions can produce falsely elevated biomarker levels and must be considered when interpreting results:<ref name="sciencedirect_renal" /><ref name="pmc_reevaluation" />

* '''Renal disease:''' Both mesothelin/SMRP and MPF levels are elevated in patients with decreased kidney function, independent of malignancy. Renal dysfunction is a major predictor of false-positive mesothelin and calretinin results
* '''Other cancers:''' Mesothelin is overexpressed in pancreatic adenocarcinoma, ovarian cancer, and lung cancer. Osteopontin is elevated in colon, breast, prostate, and lung cancer
* '''Inflammatory conditions:''' Hypertension, bronchitis, and elevated inflammatory markers can affect mesothelin concentrations
* '''Age:''' A 10-year increase in age results in approximately 2-fold more false-positive mesothelin tests

Clinical covariates including age, BMI, and glomerular filtration rate independently affect SMRP and MPF levels and should be routinely recorded when interpreting these biomarkers.<ref name="pmc_biomarkers_review" /><ref name="mesoatty_diagnosis" />

== What Is the Future of Mesothelioma Blood Testing? ==

The strongest evidence supports using biomarker panels rather than individual markers. A combination of fibulin-3 and HMGB1 achieved AUC of 0.987 for distinguishing mesothelioma from other pleural effusions (95.45% sensitivity, 92.11% specificity). A three-protein panel of mesothelin, fibulin-3, and HMGB1 achieved AUC of 0.99 with 96% sensitivity and 93% specificity. The 13-protein SOMAmer classifier demonstrated 92% overall accuracy with detection of 88% of early-stage disease.<ref name="mattioli_panel" /><ref name="pmc_hmgb1" /><ref name="pmc_somamer" /><ref name="dandell_treatment" />

The combination of protein biomarkers, miRNAs, and methylated DNA from different molecular classes represents the most promising path toward reliable early detection of mesothelioma in high-risk populations — particularly workers with documented [[Occupational_Exposure_Index|asbestos exposure]] who are under medical surveillance through [[Asbestos_Exposure_Screening_Programs|screening programs]].<ref name="pmc_mirna_prediagnostic" /><ref name="pmc_calretinin" /><ref name="mlc_diagnosis" />

{{Statute Warning}}

== Related Resources ==

* [[Mesothelioma_Diagnosis_and_Staging|Mesothelioma Diagnosis and Staging]]
* [[Mesothelioma_Biopsy_Procedures|Mesothelioma Biopsy Procedures]]
* [[Mesothelioma_Molecular_and_Genetic_Testing|Mesothelioma Molecular and Genetic Testing]]
* [[Treatment_Options|Mesothelioma Treatment Options]]
* [[Clinical_Trials|Mesothelioma Clinical Trials]]
* [[Understanding_Your_Diagnosis|Understanding Your Diagnosis]]


{{CTA Box|}}


== References ==
<references>
<ref name="pmc_biomarkers_review">[https://pmc.ncbi.nlm.nih.gov/articles/PMC5504120/ Diagnostic and Prognostic Biomarkers for Malignant Mesothelioma: An Update], PMC / National Library of Medicine</ref>
<ref name="pmc_calretinin">[https://pmc.ncbi.nlm.nih.gov/articles/PMC5450182/ Calretinin as a Blood-Based Biomarker for Mesothelioma], PMC / National Library of Medicine</ref>
<ref name="wiki_mesomark">[https://en.wikipedia.org/wiki/Mesomark_assay Mesomark Assay], Wikipedia (structural reference)</ref>
<ref name="fda_mesomark">[https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfhde/hde.cfm?id=428955 MESOMARK Humanitarian Device Exemption], U.S. Food and Drug Administration</ref>
<ref name="pmc_circulating">[https://pmc.ncbi.nlm.nih.gov/articles/PMC12691059/ Circulating Biomarkers and Targeted Therapy in Pleural Mesothelioma], PMC / National Library of Medicine</ref>
<ref name="pmc_smrp_pilot">[https://pmc.ncbi.nlm.nih.gov/articles/PMC8623660/ Pilot Study to Evaluate Serum SMRP as Marker for Clinical Monitoring of Pleural Mesothelioma], PMC / National Library of Medicine</ref>
<ref name="fujirebio">[https://www.fujirebio.com/en-us/news-events/fujirebio-diagnostics-receives-fda-approval-for-the-mesomarkr-assay-for-the-management Fujirebio Diagnostics Receives FDA Approval for MESOMARK Assay], Fujirebio Diagnostics</ref>
<ref name="bmjopen_smrp">[https://bmjopen.bmj.com/content/4/2/e004145 Diagnostic Values of Soluble Mesothelin-Related Peptides for Mesothelioma: Meta-Analysis], BMJ Open</ref>
<ref name="arup_mesomark">[https://www.aruplab.com/mesomark Soluble Mesothelin Related Peptides (MESOMARK)], ARUP Laboratories</ref>
<ref name="nejm_fibulin">[https://www.nejm.org/doi/abs/10.1056/NEJMoa1115050 Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma], New England Journal of Medicine</ref>
<ref name="pmc_fibulin_meta">[https://pmc.ncbi.nlm.nih.gov/articles/PMC5356703/ Diagnostic Value of Fibulin-3 for Malignant Pleural Mesothelioma], PMC / National Library of Medicine</ref>
<ref name="oncotarget_fibulin">[https://www.oncotarget.com/article/14712/text/ Diagnostic and Prognostic Utilities of Humoral Fibulin-3 in Malignant Mesothelioma], Oncotarget</ref>
<ref name="bmjopen_diaphragm">[https://bmjopen.bmj.com/content/6/11/e013324 Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM)], BMJ Open</ref>
<ref name="pmc_osteopontin">[https://pmc.ncbi.nlm.nih.gov/articles/PMC4073746/ Performance of Osteopontin in the Diagnosis of Malignant Pleural Mesothelioma: A Meta-Analysis], PMC / National Library of Medicine</ref>
<ref name="hindawi_mpf">[https://www.hindawi.com/journals/dm/2013/874212/ Comparison of MSLN Gene Products Mesothelin and MPF as Biomarkers for Mesothelioma], Disease Markers / Hindawi</ref>
<ref name="pmc_systematic">[https://pmc.ncbi.nlm.nih.gov/articles/PMC5355927/ Prognostication and Monitoring of Mesothelioma Using Biomarkers: A Systematic Review], PMC / National Library of Medicine</ref>
<ref name="asco_mpf">[https://ascopubs.org/doi/10.1200/PO.17.00282 Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma], JCO Precision Oncology</ref>
<ref name="oup_mpf">[https://academic.oup.com/jalm/article/3/2/166/5603053 Elevated Serum MPF as a Predictor of Poor Survival in Mesothelioma and Primary Lung Cancer], Journal of Applied Laboratory Medicine</ref>
<ref name="pmc_new_biomarkers">[https://pmc.ncbi.nlm.nih.gov/articles/PMC4356891/ Discovery of New Biomarkers for Malignant Mesothelioma], PMC / National Library of Medicine</ref>
<ref name="pmc_somamer">[https://pmc.ncbi.nlm.nih.gov/articles/PMC3463527/ Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals Using SOMAmer Technology], PMC / National Library of Medicine</ref>
<ref name="pmc_hmgb1">[https://pmc.ncbi.nlm.nih.gov/articles/PMC4867109/ HMGB1 and Its Hyperacetylated Isoform Are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and Identify Mesothelioma Patients], PMC / National Library of Medicine</ref>
<ref name="aacr_hmgb1_concern">[https://aacrjournals.org/clincancerres/article/26/6/1529/83148/Expression-of-Concern-HMGB1-and-Its Expression of Concern: HMGB1 and Its Hyperacetylated Isoform Study], Clinical Cancer Research (2020)</ref>
<ref name="exploration_mirna">[https://www.explorationpub.com/Journals/etat/Article/100228 Circulating Biomarkers in Malignant Pleural Mesothelioma], Exploration of Targeted Anti-tumor Therapy</ref>
<ref name="pmc_mirna_prediagnostic">[https://pmc.ncbi.nlm.nih.gov/articles/PMC6371620/ Are Circulating MicroRNAs Suitable for the Early Detection of Malignant Mesothelioma?], PMC / National Library of Medicine</ref>
<ref name="sciencedirect_renal">[https://www.sciencedirect.com/science/article/abs/pii/S016950021100047X Mesothelin and Kidney Function: Analysis of Relationship], Science Direct</ref>
<ref name="pmc_reevaluation">[https://pmc.ncbi.nlm.nih.gov/articles/PMC7896559/ Re-evaluation of Potential Predictors of Calretinin and Mesothelin], PMC / National Library of Medicine</ref>
<ref name="mattioli_panel">[https://mattioli1885journals.com/index.php/lamedicinadellavoro/article/view/13522 Identification of a New Potential Plasmatic Biomarker Panel for Mesothelioma Diagnosis], La Medicina del Lavoro</ref>
<ref name="dandell_diagnosis">[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis], Danziger & De Llano</ref>
<ref name="dandell_bloodtests">[https://dandell.com/mesothelioma-blood-tests/ Mesothelioma Blood Tests], Danziger & De Llano</ref>
<ref name="dandell_treatment">[https://dandell.com/mesothelioma-treatment/ Mesothelioma Treatment Options], Danziger & De Llano</ref>
<ref name="mlc_diagnosis">[https://mesotheliomalawyercenter.org/mesothelioma/diagnosis/ Mesothelioma Diagnosis], Mesothelioma Lawyer Center</ref>
<ref name="mlc_bloodtests">[https://mesotheliomalawyercenter.org/mesothelioma/diagnosis/blood-tests/ Mesothelioma Blood Tests and Biomarkers], Mesothelioma Lawyer Center</ref>
<ref name="mlc_treatment">[https://mesotheliomalawyercenter.org/mesothelioma/treatment/ Mesothelioma Treatment], Mesothelioma Lawyer Center</ref>
<ref name="mesonet_diagnosis">[https://mesothelioma.net/mesothelioma-diagnosis/ Mesothelioma Diagnosis], Mesothelioma.net</ref>
<ref name="mesonet_bloodtests">[https://mesothelioma.net/mesothelioma-blood-tests/ Mesothelioma Blood Tests], Mesothelioma.net</ref>
<ref name="mesonet_treatment">[https://mesothelioma.net/mesothelioma-treatment/ Mesothelioma Treatment], Mesothelioma.net</ref>
<ref name="mesoatty_diagnosis">[https://mesotheliomaattorney.com/mesothelioma/diagnosis/ Mesothelioma Diagnosis Guide], MesotheliomaAttorney.com</ref>
<ref name="mesoatty_bloodtests">[https://mesotheliomaattorney.com/mesothelioma/diagnosis/blood-tests/ Mesothelioma Blood Tests], MesotheliomaAttorney.com</ref>
<ref name="cancer_gov">[https://www.cancer.gov/types/mesothelioma Mesothelioma Treatment], National Cancer Institute</ref>
</references>

[[Category:Mesothelioma]]
[[Category:Medical]]
[[Category:Diagnostic]]
[[Category:Biomarkers]]
[[Category:Blood Tests]]
[[Category:Early Detection]]
[[Category:Treatment Monitoring]]